Alyeska Investment Group’s Acceleron Pharma XLRN Stock Holding History

Alyeska Investment Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100,000	Closed	-$17.2M	–	811
2021 Q3	$17.2M	Buy	100,000 +50,000	+100%	+$6.54M	0.21%	129
2021 Q2	$6.28M	Sell	50,000 -423	-0.8%	-$53.4K	0.07%	295
2021 Q1	$6.84M	Buy	+50,423	New	+$6.51M	0.09%	269
2017 Q4	–	Sell	-75,000	Closed	-$2.8M	–	556
2017 Q3	$2.8M	Buy	+75,000	New	+$2.6M	0.02%	331
2016 Q2	–	Sell	-60,000	Closed	-$1.58M	–	519
2016 Q1	$1.58M	Buy	+60,000	New	+$1.74M	0.01%	345
2013 Q4	–	Sell	-70,000	Closed	-$1.56M	–	395
2013 Q3	$1.56M	Buy	+70,000	New	+$1.51M	0.06%	245

Alyeska Investment Group's XLRN Position: Q4 2021 in Review

Alyeska Investment Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 100,000 shares — an estimated $17.2M sold.

Alyeska Investment Group first reported a position in XLRN in Q3 2013 and held it in 6 quarters. The position peaked at $17.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Alyeska Investment Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Alyeska Investment Group sold 100,000 Acceleron Pharma shares in Q4 2021, an estimated $17.2M.
Alyeska Investment Group first reported a position in Acceleron Pharma in Q3 2013 and held it in 6 quarters.
Alyeska Investment Group's Acceleron Pharma position peaked at $17.2M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Alyeska Investment Group's 13F filing for Q4 2021, filed 14 Feb 2022.